Stephanie Su
Pronouns: She/her
About
My research project
Population ageing and the spillover effects of tourism development on healthcare systemThe interaction between tourism development and population ageing is a pressing economic and policy issue, particularly for destinations where visitor flows coincide with already constrained healthcare capacity. Through an interdisciplinary lens, this study examines the spatial spillover effects of tourism development on regional healthcare system burden using England as an empirical case, test how population ageing changes the magnitude and direction of these effects, and explore policy options that effectively manage the burden.
Supervisors
The interaction between tourism development and population ageing is a pressing economic and policy issue, particularly for destinations where visitor flows coincide with already constrained healthcare capacity. Through an interdisciplinary lens, this study examines the spatial spillover effects of tourism development on regional healthcare system burden using England as an empirical case, test how population ageing changes the magnitude and direction of these effects, and explore policy options that effectively manage the burden.
ResearchResearch interests
Tourism Economics, Global Health, Visitor Economy, Economics, Public and Social Policy, International Development, International Affairs
Research interests
Tourism Economics, Global Health, Visitor Economy, Economics, Public and Social Policy, International Development, International Affairs
Publications
The Sustainable Development Goals (SDGs) include ending the epidemics of HIV, tuberculosis, and malaria by 2030. With 5 years remaining to meet this goal, and with the Global Fund to Fight AIDS, Tuberculosis and Malaria seeking funding for programmes in 2027–29, establishing what can be achieved through continued investment in combatting these diseases is crucial. We aimed to estimate the potential for impact by analysing the funding landscape and epidemiological situations of these three diseases, the costs of key programmes, and the extent of possible future progress in the countries eligible for Global Fund support. In this modelling study, we developed estimates of the financial resources needed in Global Fund-supported countries to combat HIV, tuberculosis, and malaria from the global plans produced by UNAIDS, the Stop TB Partnership, and WHO. Estimates of available resources in the coming years were obtained by assuming that national expenditure on the three diseases would grow in line with general governmental expenditures, that the Global Fund would contribute an additional $18·0 billion, and that other developmental assistance would be at the same level in real terms as the average in the period 2020–22. Epidemiological and costing models for each of the three diseases were used to quantify the possible impact in Global Fund-eligible countries (including on aggregated mortality and incidence rates). The return on investment (ROI) was computed considering both the intrinsic value of health and the direct economic benefits of the reduced risk of morbidity and premature mortality. The analysis was completed at the end of 2024 with the latest available data, which pertained to the year 2023. The focus of the projection period was 2027–29, a period for which scale-up plans and funding have not yet been committed and the period when most of the resources raised by the eighth replenishment of the Global Fund would be used. The total resource needs for the three diseases were estimated to be US$140·6 billion in 2027–29. We calculated that $111·3 billion (79%) of this need could be met from domestic financing ($69·7 billion), the Global Fund ($18·0 billion), and other external donors ($23·6 billion). Optimal use of these available resources could save 23 million lives and avert 400 million cases and new infections during 2027–29. The trajectory of the combined mortality rate for all diseases was projected to approach that needed to reach the SDG for 2030 (with a difference between the target in 2030 and the projection at the end of 2029 of between 1·5% and 15·5% of the normalised aggregated mortality rate), inequality in life expectancy between countries would be 7% lower by 2029, and 189 million fewer hospital days and 572 million fewer outpatient visits would be needed in 2027–29, saving $1·1 billion. For every $1·00 invested, there could be up to $19·00 in intrinsic health value created or $3·50 in direct economic benefits. Continued investments to combat HIV, tuberculosis, and malaria could yield enormous health gains and a high return on investment. Realising these benefits will require continued growth in national expenditure and a broad maintenance of external financing for these diseases, including a successful replenishment of the Global Fund in 2025. The Global Fund.
Background Households affected by tuberculosis (TB) often incur substantial costs, despite efforts to make TB treatment affordable. Local estimates of household costs associated with TB diagnosis and treatment are critical for quantifying the burden faced by TB-affected households and the potential impact of proposed interventions. Methods We conducted a systematic review and meta-analysis of studies published during 2015–2024 that collected data on costs incurred by TB-affected households in a low- or middle-income country (LMIC) (PROSPERO CRD42025159307). We extracted cost estimates, stratified by care-cascade phase (pre-treatment, intensive treatment, and continuation treatment) and cost category (direct medical, direct non-medical, and indirect). We fit multi-level Bayesian meta-regression models predicting per-episode costs in 2025 International Dollars for all LMIC (including those not captured in review data). Covariates included country-year matched median household income, out-of-pocket percentage of current health expenditures, and TB case detection rates, plus study- and country-random effects. We also investigated temporal trends in costs. Results We identified 122 relevant studies, of which 104 were included in quantitative analysis. Included studies represented 55,623 participants across 38 countries, surveyed during 2009–2023. Estimated country-level, per-episode costs of rifampin-susceptible TB (RS-TB) ranged from $668 (95% credible interval: $196, $1,697) to $9,156 ($1,657, $31,476). Indirect and continuation treatment costs had the highest relative burden, representing 46% (IQR: 32%, 61% and 41% (20%, 62%) of per-episode costs, respectively. Time trend estimates were small and insignificant for total TB costs [average annual increase 4·0% (95% credible interval: -4·0%, 12·0%)]. Interpretation TB-affected households still face high costs throughout the care-cascade. Costs varied across countries, category, and care phase; incorporating these differences into TB economic evaluations could improve the quantification of intervention benefits. Costs were relatively stable over time, suggesting continued efforts to reduce household economic burden of TB are needed.
Background Global investments to combat HIV, tuberculosis, and malaria (HTM) have delivered substantial health gains and may have reduced the burden placed by these diseases on the routine health system. We estimated the reduction in primary healthcare (PHC) utilization resulting from the scale-up of HTM services over 2000-2023 in 108 low- and middle-income countries. Methods and findings For each disease, we applied established mathematical models to quantify PHC utilization (outpatient visits and inpatient bed-days provided outside of HTM programs) by individuals with symptomatic HIV, tuberculosis, or malaria unable to access HTM-specific services. For each country, we estimated averted PHC utilization by comparing a scenario describing the actual scale-up of HTM services to a counterfactual scenario holding HTM service coverage constant at year 2000 levels. We applied published unit costs to estimate the averted costs resulting from reduced PHC utilization. Over 2000-2023, scale-up of HTM services averted an estimated 6.9 (95% uncertainty interval (UI) [4.4, 10.5]) billion outpatient PHC visits and 3.9 (95% UI [2.5, 5.9]) billion inpatient bed-days, representing US$135 (95% UI [71, 250]) billion in averted costs. These reductions were greatest in sub-Saharan Africa and East Asia and Pacific regions. Across study countries, these reductions represented a median of 4.4% of hospital bed capacity and 1.6% of government health spending in 2023. These percentages were 22.9% and 5.1%, respectively, for low-income countries. Our analysis did not consider changes in PHC services beyond utilization. Also, several inputs were missing in some countries, with missing values estimated using regression imputation. Conclusions Over recent decades, sustained investments in HTM services in high-burden settings have averted substantial PHC utilization and associated costs. These benefits should be considered when assessing investment impact.